Baicker Katherine
Known title: DirectorCIK: 0001537067
Associated companies
Transaction History
| LLY | ▲ Buy | Grant | 215 | $220K | 11/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 303 | $220K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 335 | $200K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 498 | $180K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 677 | $175K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.